Ran Pixin, male, 62 years old, Doctor of Medicine, professor, and doctoral supervisor. He studied at Hengyang Medical College (now the University of South China) from September 1980 to June 1985. From July 1985 to August 1987, he worked as a resident doctor at the First Affiliated Hospital of Hengyang Medical College. From September 1987 to August 1990, he pursued a master's degree at Hubei Medical College. From September 1990 to June 1993, he pursued a doctoral degree at Tongji Medical University. Since July 1993, he has been working at Guangzhou Medical College (Guangzhou Institute of Respiratory Diseases). During this period, from September 1993 to May 1994, he studied at the Institute of Basic Cardiovascular Diseases of Peking University for further studies. From February 1999 to February 2000, he studied at California State University, Northridge and the University of Southern California in the United States.

Work Experience:

He has successively served as an assistant researcher at Guangzhou Medical College (from August 1993 to December 1995), an associate professor (from January 1996 to December 2000), and a professor (from January 2001 to present).

He served as the deputy director of the Guangzhou Institute of Respiratory Diseases (from September 1995 to July 1999).

He served as the assistant to the president of Guangzhou Medical College (from March 1996 to April 2000).

He served as the vice president of Guangzhou Medical College (from April 2000 to June 2005).

He served as the president of Guangzhou Medical College (from July 2005 to October 2011).

He served as the Party secretary of Guangzhou Medical College (from October 2011 to April 2013. During this period, from October 2011 to April 2012, he took on the responsibilities of the acting president).

From May 2013 to January 2021, he served as the Party secretary of Guangzhou Medical University.

In December 2020, he served as the president of Guangzhou Medical University.

Research Directions:

His main research direction is chronic obstructive pulmonary disease. In particular, he has conducted relatively systematic research on the prevention and treatment of chronic obstructive pulmonary disease in the population and the pathogenesis of hypoxic pulmonary hypertension (HPH).